(Circulation. 2004;110:177-185.)
© 2004 American Heart Association, Inc.
Original Articles |
From the Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, Pa.
Correspondence to Nathalie Fiaschi-Taesch, PhD, Research Associate, Division of Endocrinology and Metabolism, BST E-1140, Endocrinology, University of Pittsburgh School of Medicine, 3550 Terrace St, Pittsburgh PA 15213. E-mail taeschn{at}msx.dept-med.pitt.edu
Received December 20, 2002; de novo received September 26, 2003; revision received March 9, 2004; accepted March 22, 2004.
Background Parathyroid hormonerelated protein (PTHrP), a normal product of arterial vascular smooth muscle (VSM), contains a nuclear localization signal (NLS) and at least 2 translational initiation sites, one that generates a conventional signal peptide and one that disrupts the signal peptide. These unusual features allow PTHrP either to be secreted in a paracrine/autocrine fashion, and thereby to inhibit arterial smooth muscle proliferation, or to be retained within the cytosol and to translocate into the nucleus, thereby serving as an intracrine stimulator of smooth muscle proliferation.
Methods and Results Here, we demonstrate 2 important findings. First, PTHrP dramatically increases the percentage of VSM cells in the S and in G2/M phases of the cell cycle. These effects require critical serine and threonine residues at positions Ser119, Ser130, Thr132, and Ser138 in the carboxy-terminus of PTHrP and are associated with the phosphorylation of the key cell cycle checkpoint regulator retinoblastoma protein, pRb. Second, because PTHrP devoid of the NLS serves as an inhibitor of VSM proliferation, we hypothesized that local delivery of NLS-deleted PTHrP to the arterial wall at the time of angioplasty might prevent neointimal hyperplasia. As hypothesized, using a rat carotid angioplasty model, adenoviral delivery of NLS-deleted PTHrP completely abolished the development of the neointima after angioplasty.
Conclusions PTHrP interacts with key cell cycle regulatory pathways within the arterial wall. Moreover, NLS-deleted PTHrP delivered to the arterial wall at the time of angioplasty seems to have promise as an agent that could reduce or eliminate the neointimal response to angioplasty.
Key Words: muscle, smooth proteins neointima restenosis angioplasty
This article has been cited by other articles:
![]() |
D. E. Wallis, S. Penckofer, and G. W. Sizemore The "Sunshine Deficit" and Cardiovascular Disease Circulation, September 30, 2008; 118(14): 1476 - 1485. [Full Text] [PDF] |
||||
![]() |
N. Fiaschi-Taesch, B. M. Sicari, K. Ubriani, T. Bigatel, K. K. Takane, I. Cozar-Castellano, A. Bisello, B. Law, and A. F. Stewart Cellular Mechanism Through Which Parathyroid Hormone-Related Protein Induces Proliferation in Arterial Smooth Muscle Cells: Definition of an Arterial Smooth Muscle PTHrP/p27kip1 Pathway Circ. Res., October 27, 2006; 99(9): 933 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Welsch, E. Schordan, C. Coquard, T. Massfelder, N. Fiaschi-Taesch, J.-J. Helwig, and M. Barthelmebs Abnormal Renovascular Parathyroid Hormone-1 Receptor in Hypertension: Primary Defect or Secondary to Angiotensin II Type 1 Receptor Activation? Endocrinology, September 1, 2006; 147(9): 4384 - 4391. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dittmer, M. Vetter, D. Schunke, P. N. Span, F. Sweep, C. Thomssen, and J. Dittmer Parathyroid Hormone-related Protein Regulates Tumor-relevant Genes in Breast Cancer Cells J. Biol. Chem., May 26, 2006; 281(21): 14563 - 14572. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |